CNS Pharmaceuticals, Inc. (CNSP)
CNSP moved a median of -0.93% 30 minutes after news, and -2.03% by the close. How CNSP actually reacts to news — the realized, point-in-time move the market made, measured across 236 labeled events over the last three years with zero look-ahead.
CNSP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 41% | 207 |
| 30-min | -0.93% | 33% | 216 |
| 60-min | -0.96% | 43% | 234 |
| to close | -2.03% | 40% | 235 |
| Middle 50% of CNSP reactions | -4.26% to +1.45% |
|---|---|
| Median reaction (30-min) | -0.93% |
| Measured reactions | 236 |
Half of all CNS Pharmaceuticals, Inc. news events land between -4.26% and +1.45% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CNSP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CNSP's baseline. Nothing else.
Recent CNSP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K CNS Pharmaceuticals, For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | — | +0.47% | |
| CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth | Press release | ACCESS Newswire | -1.54% | +0.55% | |
| CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference | Press release | ACCESS Newswire | +0.00% | -0.94% | |
| Form DEFA14A CNS Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | — | -6.69% | |
| Form DEF 14A CNS Pharmaceuticals, For: Sep 30 | SEC filing · Form DEF | SEC EDGAR | -0.76% | +4.03% | |
| CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation | Press release | ACCESS Newswire | +0.00% | -4.02% | |
| Form 10-Q CNS Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -4.02% | |
| Form 8-K CNS Pharmaceuticals, For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.00% | |
| CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment | Press release | ACCESS Newswire | +0.00% | -0.41% | |
| Form EFFECT CNS Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | +2.07% | +6.00% | |
| Form D CNS Pharmaceuticals, | SEC filing · Form D | SEC EDGAR | -1.61% | +2.41% | |
| Form S-3 CNS Pharmaceuticals, | SEC filing · Form S-3 | SEC EDGAR | -1.61% | +2.41% | |
| CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress | Press release | ACCESS Newswire | +1.32% | -5.47% | |
| Form 10-Q CNS Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.32% | -5.47% | |
| CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing | Press release | ACCESS Newswire | +5.89% | -14.50% | |
| Form 8-K CNS Pharmaceuticals, For: May 04 | SEC filing · Form 8-K | SEC EDGAR | +5.89% | -14.50% | |
| Form 10-K/A CNS Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.89% | +2.72% | |
| Form 10-K CNS Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -7.84% | -15.10% | |
| CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline | Press release | ACCESS Newswire | -4.75% | -17.32% | |
| Form 8-K CNS Pharmaceuticals, For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | -4.75% | -17.32% | |
| CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team | Press release | ACCESS Newswire | — | -1.88% | |
| Form 8-K CNS Pharmaceuticals, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -3.49% | |
| Form S-8 CNS Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | — | -1.88% | |
| CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation | Press release | ACCESS Newswire | -5.88% | -4.12% | |
| Form 8-K CNS Pharmaceuticals, For: Feb 10 | SEC filing · Form 8-K | SEC EDGAR | -5.88% | -4.12% | |
| CNS Pharmaceuticals Issues Letter to Shareholders | Press release | ACCESS Newswire | -2.72% | -1.92% | |
| CNS Pharmaceuticals Announces CEO Transition | Press release | ACCESS Newswire | +1.48% | -5.25% | |
| Form 8-K CNS Pharmaceuticals, For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | +1.48% | -5.25% | |
| Form 8-K CNS Pharmaceuticals, For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | — | -1.58% | |
| CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | +0.00% | +0.15% | |
| Form 10-Q CNS Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.15% | |
| Form DEFA14A CNS Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting | Press release | ACCESS Newswire | +1.96% | -1.96% | |
| Form ARS CNS Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -3.47% | -6.82% | |
| Form DEF 14A CNS Pharmaceuticals, For: Nov 17 | SEC filing · Form DEF | SEC EDGAR | +0.12% | +1.33% | |
| Form PRE 14A CNS Pharmaceuticals, For: Nov 17 | SEC filing · Form PRE | SEC EDGAR | +1.08% | -5.13% | |
| CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | ACCESS Newswire | +0.00% | -1.92% | |
| IBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc. | Press release | GlobeNewswire | -4.00% | +0.64% | |
| CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | +0.00% | -19.33% | |
| CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech | Press release | ACCESS Newswire | +4.34% | -15.66% | |
| Form 10-Q CNS Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -19.33% | |
| CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference | Press release | ACCESS Newswire | +1.26% | +0.80% | |
| Form 8-K CNS Pharmaceuticals, For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | +1.89% | -8.57% | |
| CNS Pharmaceuticals Announces Reverse Stock Split | Press release | ACCESS Newswire | -2.36% | -4.76% | |
| Form 8-K CNS Pharmaceuticals, For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | +2.55% | +0.61% | |
| CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment | Press release | ACCESS Newswire | -1.82% | +1.11% | |
| CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287 | Press release | ACCESS Newswire | +0.00% | -1.56% | |
| CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit | Press release | ACCESS Newswire | -0.96% | -2.88% | |
| CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | -2.48% | +5.79% | |
| Form 10-Q CNS Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.48% | +5.79% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CNSP section they belong to.
Where else CNSP is measured.
CNSP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CNS Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled CNSP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 236 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 33% of CNSP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CNSP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.